U.K. Microbicides Development Programme Begins Enrollment of Phase III Trial in Africa
October 26, 2005
The U.K. Microbicides Development Programme will begin enrolling women in Uganda and South Africa in a Phase III clinical trial of Lexington, Mass.-based Indevus Pharmaceuticals' experimental microbicide PRO 2000, Indevus announced on Tuesday, BBC News reports (BBC News 10/24). PRO 2000 can be applied before sexual intercourse and is formulated to prevent HIV from attaching to human cells. The 39-month trial will be conducted by MDP -- a $74 million partnership between the U.K. Department for International Development and the U.K. Medical Research Council -- and administered by the MRC Clinical Trials Unit and Imperial College London. Researchers plan to enroll more than 10,000 women in South Africa, Tanzania, Uganda and Zambia (Kaiser Daily HIV/AIDS Report, 4/7). Participants in the trial will randomly be given either a placebo or one of two strengths of PRO 2000 (Press Association/Scotsman, 10/25). The women will be asked to apply the product before sexual intercourse, and each participant also will be given condoms and HIV prevention counseling. The program has opened enrollment for the trial at clinics in Johannesburg, South Africa, and the Masaka district in Uganda and plans to open additional sites in South Africa, Tanzania and Zambia (Indevus release, 10/25).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2005 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.